What a magnificent event to present these wonderful numbers to the biggest stem cell event in the world.
http://www.isscr.org/meetings-event...meeting-2018/program/2018-program-book-errata
2018 ISSR Annual Meeting
20-23 June, 2018
Melbourne Convention & Exhibition Centre
Melbourne, Australia
Wednesday, 20 June
Plenary II: Recapitulating Development from Stem Cells 16:00-18:00
Nissim Benvenisty, Hebrew University, Israel
HAPLOID HUMAN EMBRYONIC STEM CELLS: DERIVATION AND APPLICATIONS
Thursday, 21 June
Concurrent IA: Mechanisms of Reprogramming 1: to pluripotency (13:15 to 15:15)
14:30 - 14:45 Abstract-selected speaker
Jian Shu, Broad Institute/Whitehead Institute, MA, U.S.
RECONSTRUCTION OF CELLULAR REPROGRAMMING LANDSCAPES AND TRAJECTORIES BY ANALYSIS OF LARGE-SCALE SINGLE-CELL GENE EXPRESSION
Concurrent IE: Homeostasis, Metabolism and Aging (13:15 to 15:15)
Session Chair: Amy Wagers, Harvard University, U.S.
13:15 – 13:20 Topic Overview by Chair
Concurrent IIC: Road to the Clinic I (16:00- 18:00)
17:15-17:30 Roger Barker, University of Cambridge, U.K.
LESSONS LEARNED FROM A CELL-BASED TRIAL IN PARKINSON’S DISEASE
17:30-17:55 Silviu Itescu, Mesoblast LTD., Australia
ROAD TO THE CLINIC: THE COMMERCIALIZATION OF MESENCHYMAL LINEAGE CELLS
Concurrent IID: Tissue Engineering (16:00- 18:00)
Session Chair: Mattias Lutolf, École Polytechnique Fédérale de Lausanne (EFPL), Switzerland
16:00 – 16:05 Topic Overview by Chair
Friday, 22 June
Plenary IV: New Technologies in Stem Cell Engineering
9:00 to 9:25: Fred H. Gage, Salk Institutes for Biological Studies, U.S.
IN VIVO BRAIN ORGANOID MODEL OF VASCULARIZED AND FUNCTIONAL PSC-DERIVED HUMAN BRAIN ORGANOIDS
Saturday, 22 June
Plenary VI: Cancer Stem Cells
10:40 – 11:05: Leonard I. Zon, Boston Children's Hospital, U.S.
THE START OF CANCER - STEM CELL CHANGES, CLONAL EXPANSION AND NICHE REGULATION
Concurrent IVA: Road to the Clinic 2 (13:15 to 15:15)
Session Chair: Robert Deans, BlueRock Therapeutics, U.S.
13:15 – 13:20 Topic Overview by Chair
Concurrent IVB: Epigenetics and Genetic Regulatory Networks
13:20-13:45: Jose Polo, Monash University, Australia
CHROMATIN AND TRANSCRIPTION FACTOR DYNAMICS DURING REPROGRAMMING
![]()
- Forums
- ASX - By Stock
- MSB
- Ann: Key Day 100 Survival Results In P3 GvHD Trial
MSB
mesoblast limited
Add to My Watchlist
4.15%
!
$2.31

Ann: Key Day 100 Survival Results In P3 GvHD Trial, page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$2.31 |
Change
-0.100(4.15%) |
Mkt cap ! $2.956B |
Open | High | Low | Value | Volume |
$2.33 | $2.35 | $2.15 | $30.94M | 13.57M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 75954 | $2.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.32 | 10350 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 75954 | 2.300 |
1 | 8580 | 2.290 |
2 | 10438 | 2.280 |
7 | 19928 | 2.270 |
3 | 9726 | 2.260 |
Price($) | Vol. | No. |
---|---|---|
2.320 | 10350 | 2 |
2.340 | 56503 | 6 |
2.350 | 108804 | 14 |
2.360 | 31450 | 3 |
2.380 | 18175 | 4 |
Last trade - 16.17pm 21/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |